Skip to main content
Contact Us
Subscribe
E-Edition
57°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Revance Therapeutics, Inc.
< Previous
1
2
Next >
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
May 02, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the Needham 22nd Annual Healthcare Conference
April 05, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
March 30, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in Upcoming Investor Conferences
March 07, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
February 28, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
February 28, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
February 27, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
February 23, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
February 21, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
January 09, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
January 06, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
November 22, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the Stifel 2022 Healthcare Conference
November 09, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
November 08, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
November 04, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
November 01, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
October 20, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
October 17, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
October 10, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
September 21, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal
September 19, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)
September 15, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 15, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
September 12, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces Proposed Public Offering of Common Stock
September 12, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
September 08, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
August 09, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
August 02, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
July 27, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
May 23, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.